高尿酸血症在冠状动脉非阻塞型心肌梗死预后中的预测价值

目的 探讨高尿酸血症与冠状动脉非阻塞型心肌梗死(MINOCA)患者的不良事件发生之间的潜在联系。方法 选取2019年1月—2020年6月在亳州市人民医院心内科住院的急性心肌梗死行急诊冠脉造影并确诊为MINOCA的患者，共168例，根据血尿酸水平分为高尿酸血症组(47例)和正常尿酸组(121例)。由经过培训的心内科人员通过医院电子病历系统收集相关基线资料。平均随访18个月，通过门诊复诊、电话随访、调阅电子病历等方式记录出院后随访期间的主要心脑血管不良事件(MACCE)发生情况，并以此作为随访终点事件。比较2组患者基线资料，观察2组患者的预后差异。结果 168例患者共记录到35次MACCE。高尿酸血症组发生16次MACCE,正常尿酸组发生19次MACCE。与正常尿酸组相比，高尿酸血症组的MACCE和非致死性心肌梗死发生率更高(分别为34.0%vs. 15.7%和10.6%vs. 0.8%;均P<0.05)。Kaplan-Meier生存分析曲线表明，高尿酸血症组MACCE风险与正常尿酸组生存曲线逐渐分离，且二者差异有统计学意义(log-rank P=0.003)。结论 对于MINOCA...

Hyperuricemia predicts adverse outcomes ater myocardial infarction with non-obstructive coronary arteries

  Objective  This study aimed to investigate the potential association between hyperuricemia and the adverse outcomes in myocardial infarction with non-obstructive coronary arteries (MINOCA) patients.  Methods  A total of 168 patients diagnosed with acute myocardial infarction who underwent emergency coronary angiography and were diagnosed as MINOCA in the Department of Cardiology of the People's Hospital of Bozhou from January 2019 to June 2020 were enrolled, and were divided into two groups based on the level of serum creatinine: hyperuricemia group (47 cases) and normouricemia group (121 cases). Follow-up was carried out for 18 months after discharge through outpatient visits, telephone calls, reviewing electronic medical records and clinical notes by two experienced cardiologists to obtain patient's clinical status and major adverse cardiovascular and cerebrovascular events (MACCE) or the first reported outcome case. The study also aimed to explore the association between hyperuricemia and adverse outcomes in MINOCA patients.  Results  All patients had follow-up data, of which 35 MACCE were recorded. The hyperuricemia group was associated with 16 MACCE, whereas 19 MACCE occurred in the normouricemia group. The hyperuricemia group had a higher incidence of MACCE and nonfatal myocardial infarction (MI) compared with the normouricemia group (34.0% vs. 15.7% and 10.6% vs. 0.8%, respectively; both P < 0.05). The increased risk of MACCE in the hyperuricemia group is shown in Kaplan-Meier survival curves, which demonstrated that MINOCA patients within the hyperuricemia group were clearly different from those in the normouricemia group, and this difference is statistically significant (log-rank P=0.003).  Conclusion  Hyperuricemia is associated with adverse outcomes and appears to be an independent predictor of MACCE in MINOCA patients. This finding indicates that the serum uric acid levels may serve as a surrogate biomarker related to risk prediction and adverse outcomes of MINOCA patients.